155. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets
for cancer therapy. Nat Rev Cancer 4:361–370. https://doi.org/10.1038/nrc1360
156. von Bubnoff N, Gorantla SP, Engh RA et al (2011) The low frequency of clinical resistance to
PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to
the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene
30:933–943. https://doi.org/10.1038/onc.2010.476
157. Weisberg E, Wright RD, Jiang J et al (2006) Effects of PKC412, Nilotinib, and Imatinib
against GIST-associated PDGFRA mutants with differential Imatinib sensitivity. Gastroenterology 131:1734–1742. https://doi.org/10.1053/j.gastro.2006.09.017
158. Heinrich MC, Griffith D, McKinley A et al (2012) Crenolanib inhibits the drug-resistant
PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal
tumours. Clin Cancer Res 18:4375–4384. https://doi.org/10.1158/1078-0432.CCR-12-0625
159. Smith CC, Lasater EA, Lin KC et al (2014) Crenolanib is a selective type I pan-FLT3 inhibitor.
Proc Natl Acad Sci U S A 111:5319–5324. https://doi.org/10.1073/pnas.1320661111
160. Roberts WG, Whalen PM, Soderstrom E et al (2005) Antiangiogenic and antitumour activity
of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 65:957–966
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
201
for cancer therapy. Nat Rev Cancer 4:361–370. https://doi.org/10.1038/nrc1360
156. von Bubnoff N, Gorantla SP, Engh RA et al (2011) The low frequency of clinical resistance to
PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to
the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene
30:933–943. https://doi.org/10.1038/onc.2010.476
157. Weisberg E, Wright RD, Jiang J et al (2006) Effects of PKC412, Nilotinib, and Imatinib
against GIST-associated PDGFRA mutants with differential Imatinib sensitivity. Gastroenterology 131:1734–1742. https://doi.org/10.1053/j.gastro.2006.09.017
158. Heinrich MC, Griffith D, McKinley A et al (2012) Crenolanib inhibits the drug-resistant
PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal
tumours. Clin Cancer Res 18:4375–4384. https://doi.org/10.1158/1078-0432.CCR-12-0625
159. Smith CC, Lasater EA, Lin KC et al (2014) Crenolanib is a selective type I pan-FLT3 inhibitor.
Proc Natl Acad Sci U S A 111:5319–5324. https://doi.org/10.1073/pnas.1320661111
160. Roberts WG, Whalen PM, Soderstrom E et al (2005) Antiangiogenic and antitumour activity
of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 65:957–966
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
201